Kaplan Fox is Investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for Potential Securities Law Violations
Kaplan Fox said it is investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for potential securities law violations. The firm cited Cellebrite’s Aug. 13, 2026 Q2 results: ARR of $507.8 million, below prior guidance, and a full-year ARR guidance cut of about $15 million at the midpoint, plus a CEO change replacing Tom Hogan with Shiv Ramji. CLBT shares fell about 29% to $10.80.
How this was made
The 30-second read
Why it matters
For trading, the actionable driver is the earnings and guidance package plus the abrupt leadership change, which the article directly links to a large one-day selloff.
Market read
CLBT’s guidance cut and immediate CEO change, alongside a cited cloud-permit delay, explain a sharp 29% drop and set up near-term volatility and repricing risk.
What to watch
The article does not quantify how much of the guidance cut is timing-related versus demand-related, so traders may over-discount without additional disclosure.
Background
The piece is a law-firm solicitation tied to an investigation, but it also summarizes Cellebrite’s Aug 13 Q2 results, guidance cut, and immediate CEO replacement.
Ticker impact
Cellebrite reported Q2 ARR of $507.8M, missed prior ARR projection, cut full-year ARR guidance, and named a new CEO effective immediately.
Bearish bias for the next several sessions, with elevated volatility as investors digest guidance and leadership-change implications.
The article ties the stock’s sharp 29% drop to the specific earnings/guidance miss plus the immediate CEO replacement, both of which typically drive repricing and uncertainty.
Market effects
Highlights regulatory or permitting friction risk for cloud-enabled offerings, which can pressure sentiment across surveillance/forensics software peers.
Primarily US-listed small-cap tech sentiment, with potential spillover to other US-listed cybersecurity/forensics names.
If the permit constraint is material, it can affect international deal velocity for similar vendors operating under cross-border compliance regimes.
Counterpoint
The ARR miss is framed as delay from a foreign entity permit requirement, which could be partially reversible if permits clear, limiting long-term damage.
Key entities
- public_companyCellebrite DI Ltd.
NASDAQ-listed company reporting Q2 ARR miss, cutting full-year ARR guidance, and replacing CEO Tom Hogan with Shiv Ramji effective immediately.
- law_firmKaplan Fox & Kilsheimer LLP
Plaintiffs’ securities litigation firm soliciting investors for information related to a Cellebrite investigation.
